Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring &lt;i&gt;FGF&lt;/i&gt;/&lt;i&gt;FGFR&lt;/i&gt; Aberrations: A Phase I Dose-Expansion Study

Funda Meric‐Bernstam; Rastislav Bahleda; Cinta Hierro; Marc Sanson; John Bridgewater; Hendrik‐Tobias Arkenau; Ben Tran; Robin Kate Kelley; Joon Oh Park; Milind Javle; Yaohua He; Karim A. Benhadji; Lipika Goyal

doi:10.1158/2159-8290.30834212

Abstract

Supplementary Appendix including all supplementary tables and figures

Related Publications

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa , Vaibhav Sahai , Antoine Hollebecque +16 more

Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, ...

2020 The Lancet Oncology 1455 citations

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger , Leora Horn , Leena Gandhi +26 more

Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor ...

2015 Journal of Clinical Oncology 1178 citations

Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China

Wen-rui Zhang , Kun Wang , Lu Yin +17 more

Objective: We explored whether medical health workers had more psychosocial problems than nonmedical health workers during the COVID-19 out...

2020 Psychotherapy and Psychosomatics 1695 citations

Distribution of Study Designs in Four Major US Journals of Obstetrics and Gynecology

Edmund F. Funai , Emily J. Rosenbush , Men‐Jean Lee +1 more

Objective: To classify and compare articles, based on the study design, in four leading US obstetrics and gynecology journals. Methods: One...

2001 Gynecologic and Obstetric Investigation 57 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer , Charles G. Drake , Ira Wollner +17 more

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...

2010 Journal of Clinical Oncology 2881 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Funda Meric‐Bernstam, 
                                
                                    Rastislav Bahleda, 
                                
                                    Cinta Hierro
                                
                                et al.
                            
                            (2025). 
                            Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring &lt;i&gt;FGF&lt;/i&gt;/&lt;i&gt;FGFR&lt;/i&gt; Aberrations: A Phase I Dose-Expansion Study. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30834212

Identifiers

DOI: 10.1158/2159-8290.30834212